Clinical trial
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory…
NCT00074646 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00074646 |
|---|---|
| Title | Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas |
| Official title | Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Glioblastoma, Malignant Gliomas |
| Intervention type | Drug |
| Interventions | CC-8490 |
| Enrollment | 36 |
| Start date | Dec 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Dec 19, 2003 |
| Last update posted | Jan 4, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: